

Allison Brashear

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6612704/publications.pdf>

Version: 2024-02-01

45
papers

2,980
citations

257450

24
h-index

254184

43
g-index

46
all docs

46
docs citations

46
times ranked

2494
citing authors

#	ARTICLE	IF	CITATIONS
1	Aligning academic medicine within the healthcare system: the APS-SPR virtual chat series. <i>Pediatric Research</i> , 2023, 93, 503-510.	2.3	2
2	Misfolding, altered membrane distributions, and the unfolded protein response contribute to pathogenicity differences in Na,K-ATPase ATP1A3 mutations. <i>Journal of Biological Chemistry</i> , 2021, 296, 100019.	3.4	15
3	Dystonia and Tremor. <i>Neurology</i> , 2021, 96, e563-e574.	1.1	46
4	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	3.3	2
5	AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500U/1mL and 500U/2mL dilutions. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100115.	0.9	0
6	IncobotulinumtoxinA Treatment in Upper-Limb Poststroke Spasticity in the Open-Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life. <i>PM and R</i> , 2020, 12, 491-499.	1.6	6
7	Cardiac phenotype in <i>ATP1A3</i> -related syndromes. <i>Neurology</i> , 2020, 95, e2866-e2879.	1.1	19
8	Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA. <i>Toxins</i> , 2020, 12, 661.	3.4	1
9	Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Hemiparesis in Adults with Lower Limb Spasticity Previously Treated With Other Botulinum Toxins: A Secondary Analysis of a Randomized Controlled Trial. <i>PM and R</i> , 2020, 12, 853-860.	1.6	2
10	Revising rapid-onset dystonia-parkinsonism: Broadening indications for <i>ATP1A3</i> testing. <i>Movement Disorders</i> , 2019, 34, 1528-1536.	3.9	34
11	Factors in the disease severity of ATP1A3 mutations: Impairment, misfolding, and allele competition. <i>Neurobiology of Disease</i> , 2019, 132, 104577.	4.4	31
12	Genotype-structure-phenotype relationships diverge in paralogs <i>ATP1A1</i> , <i>ATP1A2</i> , and <i>ATP1A3</i> . <i>Neurology: Genetics</i> , 2019, 5, e303.	1.9	33
13	IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. <i>Advances in Therapy</i> , 2019, 36, 187-199.	2.9	15
14	Alternating Hemiplegia of Childhood in a Person of Malay Ethnicity with Diffusion Tensor Imaging Abnormalities. <i>Journal of Movement Disorders</i> , 2019, 12, 132-134.	1.3	1
15	A 500U/2mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. <i>International Journal of Neuroscience</i> , 2018, 128, 619-626.	1.6	12
16	Gender bias in American Academy of Neurology recognition awards?. <i>Neurology</i> , 2018, 91, 291-292.	1.1	7
17	Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity. <i>Clinical Neurology and Neurosurgery</i> , 2017, 156, 1-3.	1.4	11
18	Research conference summary from the 2014 International Task Force on <i>ATP1A3</i> -Related Disorders. <i>Neurology: Genetics</i> , 2017, 3, e139.	1.9	52

#	ARTICLE	IF	CITATIONS
19	ATP1A3 Mutation in Adult Rapid-Onset Ataxia. <i>PLoS ONE</i> , 2016, 11, e0151429.	2.5	34
20	A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β 1 subunit, Lamb1. <i>ELife</i> , 2015, 4, .	6.0	21
21	Novel mutations in <i>ATP1A3</i> associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. <i>Epilepsia</i> , 2015, 56, 422-430.	5.1	107
22	Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 992-1001.	10.2	174
23	<i>ATP1A3</i> mutations. <i>Neurology</i> , 2014, 82, 468-469.	1.1	9
24	Poster 398 OnabotulinumtoxinA Treatment Reduces Pain in Patients with Upper Limb Post Stroke Spasticity. <i>PM and R</i> , 2014, 6, S324.	1.6	2
25	Distinct neurological disorders with ATP1A3 mutations. <i>Lancet Neurology</i> , The, 2014, 13, 503-514.	10.2	206
26	Treatment of cervical dystonia. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 599-606.	0.8	1
27	Commentary. <i>Movement Disorders</i> , 2013, 28, 1939-1939.	3.9	4
28	<i>ATP1A3</i> mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia. <i>Developmental Medicine and Child Neurology</i> , 2012, 54, 1065-1067.	2.1	78
29	Psychiatric disorders in rapid-onset dystonia-parkinsonism. <i>Neurology</i> , 2012, 79, 1168-1173.	1.1	60
30	Mutations in the Na ⁺ /K ⁺ -ATPase β 3 Gene ATP1A3 Are Associated with Rapid-Onset Dystonia Parkinsonism. <i>Neuron</i> , 2004, 43, 169-175.	8.1	466
31	Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the author(s) or upon any organization with which the author(s) is/are associated. <i>Archives of Physical Medicine and Rehabilitation</i> , 2004, 85, 705-709.	0.9	83
32	Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. <i>Archives of Physical Medicine and Rehabilitation</i> , 2004, 85, 1063-1069.	0.9	174
33	Use of botulinum toxin type A in poststroke spasticity. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 271-277.	2.8	2
34	Treatment with botulinum toxin type B for upper-limb spasticity. <i>Archives of Physical Medicine and Rehabilitation</i> , 2003, 84, 103-107.	0.9	33
35	Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. <i>Archives of Physical Medicine and Rehabilitation</i> , 2002, 83, 1349-1354.	0.9	212
36	Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke. <i>New England Journal of Medicine</i> , 2002, 347, 395-400.	27.0	544

#	ARTICLE	IF	CITATIONS
37	Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opinion on Investigational Drugs, 2001, 10, 2191-2199.	4.1	13
38	Cervical dystonia severity scale reliability study. Movement Disorders, 2001, 16, 1086-1090.	3.9	42
39	Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Movement Disorders, 2000, 15, 150-153.	3.9	50
40	Rapid-onset dystonia-parkinsonism: Linkage to chromosome 19q13. Annals of Neurology, 1999, 46, 176-182.	5.3	97
41	PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). Movement Disorders, 1999, 14, 132-137.	3.9	73
42	Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Annals of Neurology, 1998, 43, 521-526.	5.3	51
43	Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Movement Disorders, 1998, 13, 158-161.	3.9	48
44	The influence of the reference electrode on CMAP configuration: Leg nerve observations and an alternative reference site. , 1996, 19, 63-67.		36
45	The influence of the reference electrode on CMAP configuration. Muscle and Nerve, 1993, 16, 392-396.	2.2	71